Dexcom (DXCM) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
9 Jul, 2026Executive summary
Q3 2024 revenue reached $994.2 million, with 3% organic growth, driven by international expansion, new product launches, and record new patient starts, while U.S. sales stabilized but declined due to channel mix and rebates.
Stelo, the first OTC glucose biosensor in the U.S., launched with strong early adoption, targeting prediabetes and Type 2 diabetes, and expanded Dexcom ONE+ to 19 countries.
Chief Commercial Officer retirement announced, with CEO assuming interim commercial leadership.
$750 million share repurchase program completed, reflecting strong capital allocation.
Ended Q3 with $2.5 billion in cash, cash equivalents, and marketable securities.
Financial highlights
Q3 2024 worldwide revenue was $994.2 million, up 2% reported and 3% organic year-over-year.
U.S. revenue declined 2% to $701.9 million, while international revenue grew 12% to $292.3 million.
Non-GAAP gross profit was $625.9 million (63% margin); GAAP gross margin was 59.7%, impacted by a $24.6 million non-cash inventory charge.
Non-GAAP operating income was $212 million (21.3% margin), and adjusted EBITDA was $300.1 million (30.2% margin); net income was $179.9 million ($0.45 per share non-GAAP, $0.34 GAAP).
Operating cash flow for the first nine months was $688.1 million, up from $614.9 million in the prior year.
Outlook and guidance
2024 revenue guidance reaffirmed at $4.0–$4.05 billion (11–13% organic growth), with margin targets of ~63% gross, ~20% operating, and ~29% adjusted EBITDA.
2025 long-range plan targets $4.6 billion revenue and margin improvements, including contributions from Stelo and new launches.
Management expects continued positive operating cash flows and sufficient liquidity for at least the next 12 months.
Latest events from Dexcom
- Revenue growth and margin gains were offset by lower earnings and a major Verily charge.DXCM
Q4 2021 - Revenue grew 19% as G7 clearance and expanded CGM access strengthened growth prospects.DXCM
Q4 2022 - Revenue climbed 43% as profitability arrived and G6 capacity doubled.DXCM
Q4 2019 - 31% revenue growth and 66% gross margin, with earnings lifted by a major tax benefit.DXCM
Q4 2020 - G6-led revenue topped $1B as launch investment and the Verily charge widened losses.DXCM
Q4 2018 - Q3 revenue and margins grew, lifting FY2026 guidance and supporting a new $1B buyback.DXCM
Q3 2026 - Q4 revenue grew 26% organically as FDA submissions and G7 integrations advanced.DXCM
Q4 2023 - CONNECT data, expanded coverage, and product innovation set stage for accelerated growth.DXCM
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue rose 13%, net income 39%, margins and guidance up, $600M shares repurchased.DXCM
Q2 2026